CAJ | 학술논문

化疗是治疗中晚期胃癌的有效方法，但单纯化疗不能明显改善中晚期胃癌患者的预后。随着对胃癌发生机制的深入研究，已经发现多个促使胃癌发生的“驱动基因”，针对这些“驱动基因”而设计的靶向药物也逐渐被研发。通过靶向抑制人类表皮生长因子受体2（ Her－2）来治疗胃癌，为中晚期胃癌患者提供了一种新的治疗方法。曲妥珠单抗（Herceptin），作为Her－2单克隆抗体，是一种治疗中晚期胃癌和转移性胃癌的靶向药物，它与以铂类和氟尿嘧啶类为基础的化疗药物联合使用，可以明显改善患者的预后。因此，本文就胃癌靶向治疗及靶向治疗联合化疗临床研究做一综述。
화료시치료중만기위암적유효방법，단단순화료불능명현개선중만기위암환자적예후。수착대위암발생궤제적심입연구，이경발현다개촉사위암발생적“구동기인”，침대저사“구동기인”이설계적파향약물야축점피연발。통과파향억제인류표피생장인자수체2（ Her－2）래치료위암，위중만기위암환자제공료일충신적치료방법。곡타주단항（Herceptin），작위Her－2단극륭항체，시일충치료중만기위암화전이성위암적파향약물，타여이박류화불뇨밀정류위기출적화료약물연합사용，가이명현개선환자적예후。인차，본문취위암파향치료급파향치료연합화료림상연구주일종술。
Although chemotherapy is an effective way for advanced gastric cancer ,it does not significant-ly improve the prognosis of patients .Recently ,further researches on the mechanism of gastric cancer have led to the identification of ′driver gene′and the development of new agents that target these genes .By inhibiting the hu-man epidermal growth factor receptor 2(Her-2)for advanced gastric cancer ,it provides a new treatment for pa-tients.Trastuzumab is a kind of Her -2 monoclonal antibody ,it is the first kind of targeted therapy drug for the treatment of advanced and metastatic gastric cancer .A combination of trastuzumab with cisplatin and fluorouracil based chemotherapy can benefit patients overall survival .Therefore,in this paper,we make a review and summary of a set of recent studies related to the gastric targeted therapy .